Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Novartis and Teva represent different pharmaceutical strategies: Novartis is a stable innovator with high margins and strong cash flow, while Teva is executing a turnaround from generics to biosimilars with improving profitability but higher debt. Despite Novartis's superior financial metrics, the article recommends Teva for long-term investors due to its more attractive valuation ratios and strong drug pipeline expected to drive growth in 2027.

07/09/2026, 12:12 PM • The Motley Fool

What Is the Vanguard International Dividend Appreciation ETF (VIGI), and Who Should Buy It?

The Vanguard International Dividend Appreciation ETF (VIGI) offers exposure to 343 global stocks from developed markets with a low 0.07% expense ratio, but has delivered underwhelming returns and a modest 2.13% dividend yield. The fund is heavily concentrated in Japan (30.9%) and Canada (23%), and has been significantly outperformed by the S&P 500 over its track record. Analysts suggest more diversified alternatives like the Vanguard International High Dividend Yield ETF (VYMI) may be better for long-term investors.

07/09/2026, 11:05 AM • The Motley Fool

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

Vanguard Health Care ETF (VHT) offers broad diversification across 429 healthcare holdings with a low 0.09% expense ratio, while VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to 26 drugmakers with higher returns but greater risk. VHT is more cost-effective and diversified, while PPH has delivered superior 5-year returns and higher dividend yield despite concentration risk and a higher 0.36% expense ratio.

07/09/2026, 8:15 AM • The Motley Fool

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

07/07/2026, 6:42 AM • GlobeNewswire

Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics

Novartis has agreed to acquire Brandon Capital's portfolio company Myricx Bio for up to US$1.5 billion, including an upfront payment of US$1.1 billion plus milestone payments. Myricx Bio, a UK-based pre-clinical oncology company, has developed a novel class of N-myristoyltransferase inhibitor (NMTi) payloads for antibody-drug conjugates (ADCs) targeting solid tumors. The acquisition represents a significant exit for Brandon Capital and validates its early-stage investment in the breakthrough cancer therapeutic platform.

07/06/2026, 1:08 AM • GlobeNewswire

Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform

Novartis has agreed to acquire Myricx Bio for up to $1.5 billion ($1.1 billion upfront plus milestone payments) to advance next-generation antibody-drug conjugate (ADC) payloads using Myricx's novel N-myristoyltransferase inhibitor (NMTi) platform. The acquisition combines Novartis's oncology expertise with Myricx's differentiated ADC assets targeting solid tumors, addressing unmet needs in overcoming ADC resistance and improving tolerability.

07/06/2026, 1:05 AM • GlobeNewswire

Photodynamic Therapy Market: Durable Growth with a CAGR of 8.3% Through 2035

The global photodynamic therapy (PDT) market is expected to grow at a CAGR of 8.3% from 2023 to 2035, driven by minimally invasive treatment demand, expanding applications in oncology and dermatology, and technological innovations. North America is projected to grow at 14% CAGR, while Europe currently holds 50% market share. Over 70 PDT therapies are under clinical development, with challenges including limited tissue penetration and high system costs.

07/03/2026, 7:55 AM • GlobeNewswire

Exploring the Cancer Metabolism-Based Therapeutics Market: Key Drivers and Challenges to $26.3 Billion Growth

The cancer metabolism-based therapeutics market is projected to grow from $3.7 billion in 2026 to $26.3 billion by 2035, driven by precision medicine approaches and rising cancer prevalence. The market includes approximately 250 therapeutic programs targeting cancer metabolism vulnerabilities, with North America expected to hold over 45% market share. Key challenges include metabolic pathway complexity and cancer cell plasticity, while strategic collaborations are accelerating development.

07/03/2026, 7:54 AM • GlobeNewswire

Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued Growth

Dupilumab (Dupixent) continues strong growth with €10.7 billion in 2023 sales and $4.34 billion in Q2 2025. FDA approval for COPD in September 2024 and expansion to chronic spontaneous urticaria in children unlock new market opportunities. The drug demonstrates clinical superiority over competitors like Xolair, with market projections extending to 2034 across multiple indications and geographic regions.

07/03/2026, 4:40 AM • GlobeNewswire

3 European Stocks to Carry Investors Through the Back Half of 2026

European stocks are nearly at parity with U.S. stocks, with the Euro Stoxx 50 index up 8.2% year-to-date as of June 30, 2026. The article recommends three European stocks poised to outperform: ArcelorMittal (steel producer), ARM Holdings (semiconductor IP company), and Novartis (biopharma company). While European stock gains have been driven by currency dynamics and valuation re-rating rather than fundamental performance, these three companies offer strong earnings growth prospects for the remainder of 2026.

07/01/2026, 1:37 PM • Investing

Why I Think This Vanguard ETF Will Beat the S&P 500 Over the Next 10 Years

The article argues that the Vanguard Total International Stock ETF (VXUS) presents a compelling investment opportunity due to a significant valuation gap between international and U.S. stocks. While international stocks have underperformed the S&P 500 by a wide margin over the past decade, they now trade at substantially lower valuations, suggesting potential for outperformance over the next 10 years.

06/20/2026, 6:24 AM • The Motley Fool

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Novartis announced that Rhapsido (remibrutinib) met primary endpoints in the Phase III RemIND trial across three chronic inducible urticaria subtypes, demonstrating twice the symptom control rate versus placebo. The company has submitted an FDA application for the symptomatic dermographism subtype, with additional global regulatory filings planned for 2026. This represents the first targeted therapy for CIndU, addressing an unmet medical need affecting 29 million patients worldwide.

06/12/2026, 5:36 AM • GlobeNewswire

Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study

Novartis announced that del-brax, an investigational therapy acquired through its $12 billion acquisition of Avidity Biosciences, met primary and key secondary endpoints in a Phase 1/2 study for facioscapulohumeral muscular dystrophy (FSHD). The therapy demonstrated strong target engagement and reduced muscle injury markers, supporting the dosing regimen for the ongoing Phase 3 FORTITUDE-3 trial.

06/11/2026, 9:14 AM • Benzinga

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.

06/10/2026, 1:00 PM • GlobeNewswire

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight

The lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.

06/10/2026, 1:00 PM • GlobeNewswire